Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04393350 trial: what clinicians have said so far
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- NCT04393350 ↗
- Active, not recruiting
- Emory University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04393350 (lenvatinib plus pembrolizumab in locally advanced nonmetastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04393350 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- WINSHIP4955-20: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Kidney Cancer; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Lenvatinib; Lenvatinib Mesylate; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Treatment (lenvatinib, pembrolizumab) · Experimental
- Enrollment
- 18
- Primary outcomes
- Objective Response Rate (Complete and Partial Responses)
- Sponsor
- Emory University with Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
- Start
- Jun 22, 2020
- Primary completion
- Sep 13, 2024
- Results posted
- Yes
- Registry record
- NCT04393350 · updated Apr 20, 2026